Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1962 6
1963 3
1964 4
1965 4
1966 6
1967 3
1968 6
1969 5
1970 9
1971 13
1972 9
1973 12
1974 9
1975 9
1976 11
1977 21
1978 12
1979 16
1980 15
1981 18
1982 18
1983 19
1984 27
1985 31
1986 34
1987 61
1988 56
1989 80
1990 97
1991 96
1992 94
1993 86
1994 124
1995 145
1996 163
1997 163
1998 262
1999 285
2000 398
2001 476
2002 545
2003 683
2004 821
2005 1022
2006 1163
2007 1284
2008 1475
2009 1737
2010 1991
2011 2371
2012 2654
2013 2837
2014 2947
2015 3158
2016 3335
2017 3305
2018 3589
2019 3693
2020 3996
2021 4467
2022 3942
2023 3978
2024 3017
2025 1

Text availability

Article attribute

Article type

Publication date

Search Results

54,473 results

Results by year

Filters applied: . Clear all
Page 1
An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.
Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU, Behr J, Bouros D, Brown KK, Colby TV, Collard HR, Cordeiro CR, Cottin V, Crestani B, Drent M, Dudden RF, Egan J, Flaherty K, Hogaboam C, Inoue Y, Johkoh T, Kim DS, Kitaichi M, Loyd J, Martinez FJ, Myers J, Protzko S, Raghu G, Richeldi L, Sverzellati N, Swigris J, Valeyre D; ATS/ERS Committee on Idiopathic Interstitial Pneumonias. Travis WD, et al. Among authors: kim ds. Am J Respir Crit Care Med. 2013 Sep 15;188(6):733-48. doi: 10.1164/rccm.201308-1483ST. Am J Respir Crit Care Med. 2013. PMID: 24032382 Free PMC article.
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR; INPULSIS Trial Investigators. Richeldi L, et al. Among authors: kim ds. N Engl J Med. 2014 May 29;370(22):2071-82. doi: 10.1056/NEJMoa1402584. Epub 2014 May 18. N Engl J Med. 2014. PMID: 24836310 Free article. Clinical Trial.
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.
Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, Mazieres J, Kim DW, Mok T, Polli A, Thurm H, Calella AM, Peltz G, Solomon BJ; CROWN Trial Investigators. Shaw AT, et al. Among authors: kim dw. N Engl J Med. 2020 Nov 19;383(21):2018-2029. doi: 10.1056/NEJMoa2027187. N Engl J Med. 2020. PMID: 33207094 Clinical Trial.
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.
Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schünemann HJ; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. Raghu G, et al. Among authors: kim ds. Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824. doi: 10.1164/rccm.2009-040GL. Am J Respir Crit Care Med. 2011. PMID: 21471066 Free PMC article.
Intensive vs Conventional Blood Pressure Lowering After Endovascular Thrombectomy in Acute Ischemic Stroke: The OPTIMAL-BP Randomized Clinical Trial.
Nam HS, Kim YD, Heo J, Lee H, Jung JW, Choi JK, Lee IH, Lim IH, Hong SH, Baik M, Kim BM, Kim DJ, Shin NY, Cho BH, Ahn SH, Park H, Sohn SI, Hong JH, Song TJ, Chang Y, Kim GS, Seo KD, Lee K, Chang JY, Seo JH, Lee S, Baek JH, Cho HJ, Shin DH, Kim J, Yoo J, Lee KY, Jung YH, Hwang YH, Kim CK, Kim JG, Lee CJ, Park S, Lee HS, Kwon SU, Bang OY, Anderson CS, Heo JH; OPTIMAL-BP Trial Investigators. Nam HS, et al. Among authors: kim dj. JAMA. 2023 Sep 5;330(9):832-842. doi: 10.1001/jama.2023.14590. JAMA. 2023. PMID: 37668619 Free PMC article. Clinical Trial.
Disruption of sugar nucleotide clearance is a therapeutic vulnerability of cancer cells.
Doshi MB, Lee N, Tseyang T, Ponomarova O, Goel HL, Spears M, Li R, Zhu LJ, Ashwood C, Simin K, Jang C, Mercurio AM, Walhout AJM, Spinelli JB, Kim D. Doshi MB, et al. Among authors: kim d. Nature. 2023 Nov;623(7987):625-632. doi: 10.1038/s41586-023-06676-3. Epub 2023 Oct 25. Nature. 2023. PMID: 37880368 Free PMC article.
First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F; PROFILE 1014 Investigators. Solomon BJ, et al. Among authors: kim dw. N Engl J Med. 2014 Dec 4;371(23):2167-77. doi: 10.1056/NEJMoa1408440. N Engl J Med. 2014. PMID: 25470694 Free article. Clinical Trial.
Response.
Choi JY, Kim KU, Kim DK, Kim YI, Kim TH, Lee WY, Park SJ, Park YB, Song JW, Shin KC, Um SJ, Yoo KH, Yoon HK, Lee CY, Lee HS, Leem AY, Choi WI, Lim SY, Rhee CK; Korean Pulmonary Rehabilitation Study Group. Choi JY, et al. Among authors: kim dk. Chest. 2024 Apr;165(4):e126-e128. doi: 10.1016/j.chest.2023.11.003. Chest. 2024. PMID: 38599758 No abstract available.
54,473 results
You have reached the last available page of results. Please see the User Guide for more information.